The document discusses experimental study designs and randomized clinical trials. It provides information on the different phases of clinical trials including objectives, demographics, and goals. Phase I trials test safety and dosing in small groups. Phase II explores biological effects and estimates response rates. Phase III confirms efficacy in larger and more diverse populations to provide evidence for marketing approval. Randomization, blinding, and placebos are used to reduce bias. Experimental studies directly manipulate variables under controlled conditions to measure outcomes compared to control groups.
Steps in conducting a RCT
1. Drawing up a protocol
2. Selecting Reference & Experimental population
3. Randomization
4. Manipulation or Intervention
5. Follow up
6. Assessment of outcome
1. Drawing up a protocol
Aims and objectives of the study
Questions to be answered
Criteria for the selection of study and control groups
Size of the sample & allocation of subjects in both groups
Treatment to be applied - when, where, how
Standardization of working procedures and
Schedules as well as responsibilities of persons involved in the trial up to the stage of evaluation of outcome of the study.
2. Selecting Reference and Experimental Populations
Reference or target population - Population to which the findings of the trial, if found successful, are expected to be applicable (Eg: drugs, vaccines, etc.)
Experimental or Study population
Derived from the Reference population
Has same characteristics as the Reference population
Actual population that participates in the experimental study
Must give informed consent - Should be qualified or eligible for the trial
3. Randomization
Heart of the control trial
Procedure:
Participants are allocated into study and control groups
Eliminates bias and allows comparability
By random allocation every individual gets an equal chance for being allocated in to either groups.
4. Manipulation/ Intervention
Having formed the study and control group, the next step is to intervene or manipulate the study (experimental) group by deliberate application or withdrawal or reduction of a suspected causal factor
Eg: Drug, Vaccine, Dietary component, a habit
5. Follow up
Implies examination of the experimental and control group subjects at defined intervals of time in a standard manner, with equal intensity, under the same given circumstances in the same time frame till final assessment of outcome.
Attrition:
Inevitable losses to follow up (death, migration, loss of interest)
6. Assessment
a. Positive results:
Reduced incidence or severity of disease
Reduced cost to health service
Appropriate outcome in the study
b. Negative results:
Increased severity or frequency of side effects
Complications
Deaths
BIAS:
Any systematic error in the determination of association and outcome.
Bias may arise from errors of assessment of outcome due to human element
Subjective bias
Observer bias
Evaluation bias
1. Subjective Bias:
Participants, subjectively feel better or report improvement if they knew they were receiving a new form of treatment. This is known as “Subject variation”.
2. Observer Bias:
Investigator measuring the outcome of a therapeutic trial may be influenced if he knows beforehand the particular procedure or therapy to which the patient has been subjected.
3. Evaluation Bias:
Investigator may subconsciously give a favorable report of the outcome of the trial.
Blinding:
1. Single Blind Trial: Participant
2. Double Blind: Partcipant + Investigator
3. Triple Blind: Participant + Investigator + Data Analyzer
Randomized control trial is so called because the patients who constitute the unit of study are allocated into ‘study group’ and ‘control group’ at random depending upon whether they receive or do not receive the intervention.
RANDOMIZED CONTROL trials
an assessment method
questions validity and applicability of many preventive and therapeutic procedures
reference Park's Preventive and social medicine
Randomized Control Trials
Enigma of Blinding Unraveled
Introduction
RCT
Steps in a RCT
Allocation Concealment
Bias in RCT
Phases in RCT
Types of RCT
Study Designs of RCT
Blinding
Methods of Blinding in different trials
Assessment of Blinding
Un-blinding
Current Scenario of Blinding
CONSORT
Conclusion
References
Steps in conducting a RCT
1. Drawing up a protocol
2. Selecting Reference & Experimental population
3. Randomization
4. Manipulation or Intervention
5. Follow up
6. Assessment of outcome
1. Drawing up a protocol
Aims and objectives of the study
Questions to be answered
Criteria for the selection of study and control groups
Size of the sample & allocation of subjects in both groups
Treatment to be applied - when, where, how
Standardization of working procedures and
Schedules as well as responsibilities of persons involved in the trial up to the stage of evaluation of outcome of the study.
2. Selecting Reference and Experimental Populations
Reference or target population - Population to which the findings of the trial, if found successful, are expected to be applicable (Eg: drugs, vaccines, etc.)
Experimental or Study population
Derived from the Reference population
Has same characteristics as the Reference population
Actual population that participates in the experimental study
Must give informed consent - Should be qualified or eligible for the trial
3. Randomization
Heart of the control trial
Procedure:
Participants are allocated into study and control groups
Eliminates bias and allows comparability
By random allocation every individual gets an equal chance for being allocated in to either groups.
4. Manipulation/ Intervention
Having formed the study and control group, the next step is to intervene or manipulate the study (experimental) group by deliberate application or withdrawal or reduction of a suspected causal factor
Eg: Drug, Vaccine, Dietary component, a habit
5. Follow up
Implies examination of the experimental and control group subjects at defined intervals of time in a standard manner, with equal intensity, under the same given circumstances in the same time frame till final assessment of outcome.
Attrition:
Inevitable losses to follow up (death, migration, loss of interest)
6. Assessment
a. Positive results:
Reduced incidence or severity of disease
Reduced cost to health service
Appropriate outcome in the study
b. Negative results:
Increased severity or frequency of side effects
Complications
Deaths
BIAS:
Any systematic error in the determination of association and outcome.
Bias may arise from errors of assessment of outcome due to human element
Subjective bias
Observer bias
Evaluation bias
1. Subjective Bias:
Participants, subjectively feel better or report improvement if they knew they were receiving a new form of treatment. This is known as “Subject variation”.
2. Observer Bias:
Investigator measuring the outcome of a therapeutic trial may be influenced if he knows beforehand the particular procedure or therapy to which the patient has been subjected.
3. Evaluation Bias:
Investigator may subconsciously give a favorable report of the outcome of the trial.
Blinding:
1. Single Blind Trial: Participant
2. Double Blind: Partcipant + Investigator
3. Triple Blind: Participant + Investigator + Data Analyzer
Randomized control trial is so called because the patients who constitute the unit of study are allocated into ‘study group’ and ‘control group’ at random depending upon whether they receive or do not receive the intervention.
RANDOMIZED CONTROL trials
an assessment method
questions validity and applicability of many preventive and therapeutic procedures
reference Park's Preventive and social medicine
Randomized Control Trials
Enigma of Blinding Unraveled
Introduction
RCT
Steps in a RCT
Allocation Concealment
Bias in RCT
Phases in RCT
Types of RCT
Study Designs of RCT
Blinding
Methods of Blinding in different trials
Assessment of Blinding
Un-blinding
Current Scenario of Blinding
CONSORT
Conclusion
References
NEED FOR RESEARCH
Research is a systemic process of collecting and analyzing information to increase the understanding of the phenomenon under study.
It strengthens pharmacist-provided services, builds the evidence base for developing and commissioning new services, improves patient care and contributes to health service knowledge.
Phase I studies: Are done on healthy volunteers who agree to take the study drug to help the doctors determine how safe the drug is and if there are any side effects. Usually a small number of subjects (20-100) participate in Phase I studies. Approximately 70% of new drugs will pass this phase.
Phase II studies: Measure the effect of the new drug in patients with the disease or disorder to be treated. The main purpose is to determine safety and effectiveness of the new drug. Usually several hundred patients participate. These studies are usually “Double-blinded, randomized and controlled”.
Phase III studies: also use patients with the disorder to be treated by the new drug. These studies are done to gain a more thorough understanding of the effectiveness, benefits and side effects of the study drug.
NEED FOR DESIGN OF EXPERIMENTS
Design of experiments (DOE) is defined as a branch of applied statistics that deals with planning, conducting, analyzing, and interpreting controlled tests to evaluate the factors that control the value of a parameter or group of parameters.
DOE is a powerful data collection and analysis tool that can be used in a variety of experimental situations.
1. PRE-EXPERIMENTAL DESIGN
In pre-experimental research design, either a group or various dependent groups are observed for the effect of the application of an independent variable which is presumed to cause change.
It is the simplest form of experimental research design and is treated with no control group
2. TRUE EXPERIMENTAL DESIGN
The true experimental research design relies on statistical analysis to approve or disprove a hypothesis. It is the most accurate type of experimental design and may be carried out with or without a pretest on at least 2 randomly assigned dependent subjects.
The true experimental research design must contain a control group, a variable that can be manipulated by the researcher, and the distribution must be random.
3. QUASI EXPERIMENTAL DESIGN
The word "quasi" means partial, half, or pseudo. Therefore, the quasi-experimental research bearing a resemblance to the true experimental research, but not the same. In quasi-experiments, the participants are not randomly assigned, and as such, they are used in settings where randomization is difficult or impossible.
This is very common in educational research, where administrators are unwilling to allow the random selection of students for experimental samples.
PLAGIARISM
The word Plagiarism is derived from the Latin word Plagiarius, which means abducting, kidnapping, seducing, or plundering.
The randomised controlled trial (RCT) .pptxPRITIBISANE
Randomized controlled trials (RCT) are prospective studies that measure the effectiveness of a new intervention or treatment.
Randomization reduces bias and provides a rigorous tool to examine cause-effect relationships between an intervention and outcome
NEED FOR RESEARCH
Research is a systemic process of collecting and analyzing information to increase the understanding of the phenomenon under study.
It strengthens pharmacist-provided services, builds the evidence base for developing and commissioning new services, improves patient care and contributes to health service knowledge.
Phase I studies: Are done on healthy volunteers who agree to take the study drug to help the doctors determine how safe the drug is and if there are any side effects. Usually a small number of subjects (20-100) participate in Phase I studies. Approximately 70% of new drugs will pass this phase.
Phase II studies: Measure the effect of the new drug in patients with the disease or disorder to be treated. The main purpose is to determine safety and effectiveness of the new drug. Usually several hundred patients participate. These studies are usually “Double-blinded, randomized and controlled”.
Phase III studies: also use patients with the disorder to be treated by the new drug. These studies are done to gain a more thorough understanding of the effectiveness, benefits and side effects of the study drug.
NEED FOR DESIGN OF EXPERIMENTS
Design of experiments (DOE) is defined as a branch of applied statistics that deals with planning, conducting, analyzing, and interpreting controlled tests to evaluate the factors that control the value of a parameter or group of parameters.
DOE is a powerful data collection and analysis tool that can be used in a variety of experimental situations.
1. PRE-EXPERIMENTAL DESIGN
In pre-experimental research design, either a group or various dependent groups are observed for the effect of the application of an independent variable which is presumed to cause change.
It is the simplest form of experimental research design and is treated with no control group
2. TRUE EXPERIMENTAL DESIGN
The true experimental research design relies on statistical analysis to approve or disprove a hypothesis. It is the most accurate type of experimental design and may be carried out with or without a pretest on at least 2 randomly assigned dependent subjects.
The true experimental research design must contain a control group, a variable that can be manipulated by the researcher, and the distribution must be random.
3. QUASI EXPERIMENTAL DESIGN
The word "quasi" means partial, half, or pseudo. Therefore, the quasi-experimental research bearing a resemblance to the true experimental research, but not the same. In quasi-experiments, the participants are not randomly assigned, and as such, they are used in settings where randomization is difficult or impossible.
This is very common in educational research, where administrators are unwilling to allow the random selection of students for experimental samples.
PLAGIARISM
The word Plagiarism is derived from the Latin word Plagiarius, which means abducting, kidnapping, seducing, or plundering.
The randomised controlled trial (RCT) .pptxPRITIBISANE
Randomized controlled trials (RCT) are prospective studies that measure the effectiveness of a new intervention or treatment.
Randomization reduces bias and provides a rigorous tool to examine cause-effect relationships between an intervention and outcome
The Art Pastor's Guide to Sabbath | Steve ThomasonSteve Thomason
What is the purpose of the Sabbath Law in the Torah. It is interesting to compare how the context of the law shifts from Exodus to Deuteronomy. Who gets to rest, and why?
The Roman Empire A Historical Colossus.pdfkaushalkr1407
The Roman Empire, a vast and enduring power, stands as one of history's most remarkable civilizations, leaving an indelible imprint on the world. It emerged from the Roman Republic, transitioning into an imperial powerhouse under the leadership of Augustus Caesar in 27 BCE. This transformation marked the beginning of an era defined by unprecedented territorial expansion, architectural marvels, and profound cultural influence.
The empire's roots lie in the city of Rome, founded, according to legend, by Romulus in 753 BCE. Over centuries, Rome evolved from a small settlement to a formidable republic, characterized by a complex political system with elected officials and checks on power. However, internal strife, class conflicts, and military ambitions paved the way for the end of the Republic. Julius Caesar’s dictatorship and subsequent assassination in 44 BCE created a power vacuum, leading to a civil war. Octavian, later Augustus, emerged victorious, heralding the Roman Empire’s birth.
Under Augustus, the empire experienced the Pax Romana, a 200-year period of relative peace and stability. Augustus reformed the military, established efficient administrative systems, and initiated grand construction projects. The empire's borders expanded, encompassing territories from Britain to Egypt and from Spain to the Euphrates. Roman legions, renowned for their discipline and engineering prowess, secured and maintained these vast territories, building roads, fortifications, and cities that facilitated control and integration.
The Roman Empire’s society was hierarchical, with a rigid class system. At the top were the patricians, wealthy elites who held significant political power. Below them were the plebeians, free citizens with limited political influence, and the vast numbers of slaves who formed the backbone of the economy. The family unit was central, governed by the paterfamilias, the male head who held absolute authority.
Culturally, the Romans were eclectic, absorbing and adapting elements from the civilizations they encountered, particularly the Greeks. Roman art, literature, and philosophy reflected this synthesis, creating a rich cultural tapestry. Latin, the Roman language, became the lingua franca of the Western world, influencing numerous modern languages.
Roman architecture and engineering achievements were monumental. They perfected the arch, vault, and dome, constructing enduring structures like the Colosseum, Pantheon, and aqueducts. These engineering marvels not only showcased Roman ingenuity but also served practical purposes, from public entertainment to water supply.
How to Split Bills in the Odoo 17 POS ModuleCeline George
Bills have a main role in point of sale procedure. It will help to track sales, handling payments and giving receipts to customers. Bill splitting also has an important role in POS. For example, If some friends come together for dinner and if they want to divide the bill then it is possible by POS bill splitting. This slide will show how to split bills in odoo 17 POS.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
We all have good and bad thoughts from time to time and situation to situation. We are bombarded daily with spiraling thoughts(both negative and positive) creating all-consuming feel , making us difficult to manage with associated suffering. Good thoughts are like our Mob Signal (Positive thought) amidst noise(negative thought) in the atmosphere. Negative thoughts like noise outweigh positive thoughts. These thoughts often create unwanted confusion, trouble, stress and frustration in our mind as well as chaos in our physical world. Negative thoughts are also known as “distorted thinking”.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
Palestine last event orientationfvgnh .pptxRaedMohamed3
An EFL lesson about the current events in Palestine. It is intended to be for intermediate students who wish to increase their listening skills through a short lesson in power point.
3. Experimental studies
• In experimental research, the study subjects are
observed under predetermined conditions using carefully
designed approaches to data & specimens
• The gold standard of clinical research
4. The experimental study designs differ from
the analytical study designs
1. The conditions in which the study is carried are under direct
control of the investigator
2. The experimental studies involve some action or
intervention or manipulation in the experiment group while
making no change in the control group
3. In analytical studies, no action but only observation of the
natural course of events or outcomes
5. The aims of experimental studies
1. To provide scientific evidence of etiological or risk
factors to permit modification or control of disease
2. To provide a method of measuring the
effectiveness or efficiency of the health services
for prevention, control & treatment of disease and
to improve the health of the community
6. GOALS OF CLINICAL TRIALS
Finding Drugs or
Treatments that
WORK
Those that
do
NOT WORK
7. USES OF CLINICAL TRIALS
• Treatment: test experimental treatments, combinations of
drugs, new approaches
• Prevention: look for better way to prevent disease or its
recurrence
• Diagnostic: develop better tests
• Screening: to detect diseases or health conditions
• Quality of Life (or Supportive Care): improve comfort and
QOL in chronic disease states
8. The disadvantages of the experimental studies
•They are costly
• Ethical problems
• Feasibility
9. CLINICAL TRIAL DESIGN
• In early smaller studies, where the drug is
being tested for safety and dose, each
person who participates gets the new drug
being tested
• In the following larger trials, doctors
compare the new drug with another
treatment to see which works better on
participants
10. • The later larger trials, may work like
this:
One group of
participants gets the
new drug
The other group gets a drug that
is used to treat the problem
OR
gets a “look alike” pill that
contains no drug
(called a placebo)
11. COMMON CLINICAL TRIAL TERMS
CONTROLLED STUDY: A study in which a test article is
compared with a treatment / placebo
A test drug is given to one group of people. This group is
often called the “treatment group”
Another drug, or no drug, is given to a second group of
people with the same illness. This is often called the “control
group”
Then the results of the two groups are compared
12. PLACEBO
• A pill, liquid, or powder that contains no drug
and has no treatment value.
• A placebo looks just like the real drug.
14. BLINDED STUDY
• A study in which the research subject or the investigator (or
both) are unaware of what trial product the subject is taking
Single-Blinded: Subjects do not know what treatment they
are getting but their research doctor and team do.
Double-Blinded: Neither the subject nor the research doctor
knows which treatment the subject is getting
17. RCT DESIGNS
[1] According to exposure to intervention:
Parallel design Each group is subjected one
intervention ( the most common design)
Group A
Group B
TREATMENT A
TREATMENT B / Placebo
18. RCT DESIGNS
[1] According to exposure to intervention:
Cross – Over design Each participant is given
both interventions in successive periods. Each
participant acts as his or her own control.
Treatment Placebo
TREATMENT A TREATMENT B
19. RCT DESIGNS
[1] According to exposure to intervention
Factorial design: When interventions are
compared separately, in combination and
against a control in different groups.
TREATMENT A
TREATMENT B
TREATMENT A +B
PLACEBO
Group A
Group B
Group C
Group D
21. RCT DESIGNS
[2] According to “Blindness” to the interventions
Open RCT everybody involved in the trial knows which
intervention is given to each participant
Single blind RCT either the participants or the investigators do
not know the identity of interventions
Double blind RCT Both the participants or the investigators do
not know the identity of the interventions
Triple blinded RCT: Participant, investigators or person who
evaluates do not know the identity of the intervention
22. Non-randomized trials
Those departing from strict randomization for
practical purposes but in such a manner that non-
randomization does not seriously affect the
theoretical basis of conclusions
23. The quasi-experimental study designs
In this design the control over the external
factors is not possible and this might alter the
outcome variables
24. Phases of Clinical Trial
• Phase I : maximum tolerated dose
• Phase II : effectiveness, safety
• Phase III : efficacy, safety
• Phase IV : effectiveness, compliance and
safety
25. RISKS AND BENEFITS OF CLINICAL TRIALS
• Risks:
• Unpleasant or serious side effects
• You may receive a placebo
• No guarantee that the experimental drug will be an effective
treatment for you
• Benefits:
• May experience health benefits from a new treatment
• Free lab tests and expert treatment
• Contributing to the development of a new medication
26. The features of the experimental study designs
• Random allocation of individuals to experimental & control groups
• Systematic manipulation of the experimental group
• Control over the other important factors affecting experimental &
control groups
• Measurement of some outcome variables with which to compare two
groups
27. The basic steps in conduct of randomized
controlled trials
1. Drawing a protocol
2. Selecting reference & experimental population
3. Randomization
4. Manipulation or intervention
5. Follow up
6. Assessment of the outcome
29. The protocol
One of the essential features of the randomized trials
The protocol specifies:
1. The objectives
2. The selection criteria
3. The sample size
4. The procedures of allocation of the subjects into
experimental and control groups
5. Outcomes & endpoints
6. The treatment applied: how, where and to what types of patients
7. The details of the scientific techniques and investigations
30. Once a protocol has been evolved, it
should be strictly adhered to
throughout the study
(Protocol Violation)
31. Selection of the reference & the
experimental populations
The reference population:
• It is the population to which the findings of the trial, if
found to be successful, are expected to be applicable
32. The experimental population:
• The experimental (study) population is derived from the
reference population
• It is the actual population that participates in the experimental
study
• It should be randomly selected from the reference population
• If the study population differs from the reference population, it
may not be possible to generalize the findings to the reference
population
33. Participants or the volunteers of the experiment must fulfill
the following criteria:
• They must give informed consent
•They should be representative of the reference population
• They should be eligible or qualified for the trial
34. Randomization
• Randomization is the statistical procedure by
which the participants are allocated into groups
usually called study & control groups to receive
or not to receive an experimental or therapeutic
procedure or intervention.
35. • Randomization aims to make the groups comparable
• Randomization ensures that the investigator has no
control over the allocation of the participants to either the
study or control group, thus eliminating the selection
bias
• Every individual has an equal chance of being allocated
into either group
• Randomization is best done by using statistical random
table
36. The essential difference between a randomized trial and analytical
study is that:
• In the latter there is no randomization because differentiation
into cases & controls exposed and non-exposed groups has
already taken place
• Thus the only option left to ensure comparability in analytical
studies is by matching
37. MANIPULATION
• Manipulation or intervention is usually done by application or
withdrawal of the suspected factor e.g. drugs, vaccine or
dietary factor
• This manipulation creates an independent variable (drug,
vaccine or new procedure) whose effect is then determined
by the measurement of the final outcome which constitutes
the dependent variable e.g. incidence of disease, recovery
38. FOLLOW UP
• This includes examination of the study & control
groups subjects at defined intervals of time in
standard manner under the same conditions in the
same time frame till the final assessment
Main difficulties encountered in the follow up process
include:
• Attrition, death, migration, displacement and loss of
interest
39. Assessment
The final assessment of the trial is carried in terms of:
• Positive results: these include the benefits of the
experimental study such as reduced incidence of the
disease or severity of the disease, cost of health
services or other appropriate outcome
40. • Negative results: these include the severity
& frequency of side-effects and complications
• The incidence of positive/negative results is
compared in both groups and the differences
are tested statistically
41. BIAS
Bias is the systematic difference between observed results
and the actual results
Sources of bias:
1. participant’s bias:
The participants report subjectively that they feel better or
improved if they knew that they were receiving new
treatment
42. 2. Observer’s bias:
The influence of the investigator measuring the
outcome of the trial if he knew beforehand the
particular procedure to which the patient has been
subjected
3. Evaluation bias:
There may be bias in evaluation as the investigator
may involuntarily give favorable report of the
outcome of the study
43. How to reduce the sources of bias?
1. Randomization
2. Blinding
44. Blinding is carried in three ways:
1. Single blind trial: the trial is so planned that the
participant is not aware whether he belongs to the
study or control group.
2. Double blind trial: the trial is so planned that
neither the doctor nor the participant is aware of
the group allocation and treatment received.
45. 3. Triple-blind trial:
• The trial is so planned that the participant, the
investigator& the person analyzing the data are
all blind.
• This is the ideal but double-blinding is the
most commonly used.
46. PHASES OF CLINICAL TRIALS
• A properly planned and implemented clinical trial is a
powerful technique for assessing the effectiveness of an
intervention
• A clinical trial is a prospective study comparing the effect
of intervention(s) against a control in human beings
• A clinical trial is prospective rather than retrospective
47. • Study participants must be followed foreword in
time.
• Follow up of the study subjects overtime without
active intervention may measure the natural
history of disease but this is not a clinical trial
48. Clinical trials Phases
Phase (I):
• The first step or phase is to understand how well the
intervention can be tolerated in a small number of healthy
individuals or sometimes patients
• It does not meet the standard definition of a clinical trial
• Most phase I designs are relatively simple
49. • Evaluating drugs, needs first step is to estimate how a dose can
be administered before unacceptable toxicity is experienced by
patients
• This dose is usually called maximally tolerated dose (MTD)
50. PHASE I OBJECTIVES
• Main purpose: assessing safety of drug
• Human Pharmacology
• Typically non-therapeutic objectives
• Determine tolerability of dose range expected to be
needed for later trials (Maximum tolerated Dose -MTD)
• Determine nature of adverse reactions that can be
expected
• Assess clearance of drug and to anticipate possible
accumulation of parent drug or metabolites and
potential drug-drug interactions
51. PHASE I DEMOGRAPHICS
• Usually healthy volunteers or certain types of patients (e.g.
new chemotherapeutic agent for cancer patients with end
stage disease)
• Often conducted in a medical setting
• 20-100 patients
• Trials can last up to several months
• Open label –everyone knows what they are getting.
• 70% of drugs successfully complete Phase I and continue
on to Phase II
52. Phase (II) trials
• Once the MTD is established: the next step is to
evaluate whether the drug has any biological
effect and to estimate the rate of adverse effects.
53. • If the design of phase I has not been adequate, the
investigator may evaluate the dose
• phase II design depends on the quality of adequacy of
phase I
• The design usually encounters a limited number of
patients and then the response rate is estimated
54. • If the response rate is less than the 20%: the drug is
omitted.
• If the response is greater than 20%: more patients
are recruited according to the precision desired:
usually 10-20
55. PHASE II OBJECTIVES
Therapeutic Exploratory
Main purpose: assessing efficacy for particular
indication (Efficacy-A product's ability to produce
beneficial effects on the course or duration of a
disease)
Initial evaluation:
Safety (side-effect)
Well-controlled, closely monitored studies
Active or placebo controlled -- double blind
Includes dose-response and/or dosing schedule
studies
Determine dose and regimen for Phase III
56. PHASE II DEMOGRAPHICS
• 200-300 (up to 1000) patients with targeted indication
(Relevant disease)
• Diseased patients; selected by relatively narrow
criteria
• Trials last from several months to 2 years
• Experienced physicians in the specialty
• Early Phase II trials may be called Phase 2a or pilot
studies
• 33% of drugs successfully complete Phase II and
continue on to Phase III
57. Phase III
• Phase III trials have a short period of evaluation
• Purpose: Confirm efficacy, monitor adverse reactions from long term
use
• In Phase III studies, a drug is tested under conditions more closely
resembling those under which the drug would be used if approved
for marketing
• The goal is to gather additional information about efficacy and
tolerability that is needed to evaluate the overall benefit-risk
relationship of the drug and to provide an adequate basis for
physician labeling
• Focus on effectiveness but knowledge on safety is also necessary
58. PHASE III OBJECTIVES
• Therapeutic Confirmatory
• Main purpose: safety, effectiveness - confirm therapeutic
benefit for use in intended indication and recipient population
• Effectiveness-The desired measure of a drug's influence on a
disease condition as proved by substantial evidence from
adequate and well-controlled investigations such as clinical
trials
• Evaluate overall benefit-risk relationship
• Provide adequate basis for marketing approval
• Extrapolate results to put in labeling
• 25-30% of drugs complete Phase 3 trials
59. PHASE 3 DEMOGRAPHICS
• Several hundred to several thousand
patients (250 – 1000 patients)
• Patients with the disease; more diverse
population
• Inclusion/Exclusion criteria less
restrictive
• Trials last from 1-4 years
• Less experienced investigators -
Approaches general use (the “real
world population)
• Overall: on average, 20%
of drugs ultimately gain FDA
approval to market
60. PHASE IV OR POST MARKETING
SURVEILLANCE
• No fixed duration / patient population
• Starts immediately after marketing
• Report all acute adverse reactions (ADRs)
• Helps to detect
• Rare ADRs
• Drug interactions
• Also new uses for drugs [Sometimes called Phase V]
• Do not involve control groups to evaluate properly the
proper role of an intervention
61. 2. PREVENTIVE TRIALS
• In general the term preventive trials implies trials of
primary preventive measures.
• The trials are designed to prevent or eliminate disease
on an experimental basis.
• The most frequently occurring type of preventive trials
are the trials of vaccines and chemoprophylaxis.
62. DESIGN OF A RANDOMIZED PREVENTIVE
CONTROL TRIAL